PVP Labs to Showcase Breakthrough Peptide Therapy Pipeline at LSX Investival

The company will highlight its non-addictive pain medication Taphalgin® at the upcoming industry event.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

PVP Labs, a pharmaceutical company focused on developing innovative peptide-based therapies, announced that it will showcase its breakthrough peptide therapy pipeline and its non-addictive pain medication Taphalgin® at the upcoming LSX Investival conference in Miami, Florida.

Why it matters

PVP Labs' presentation at LSX Investival will give investors and industry leaders a first look at the company's promising peptide-based drug candidates, which could offer new treatment options in areas like pain management, potentially reducing reliance on highly addictive opioid painkillers.

The details

At the conference, PVP Labs plans to highlight Taphalgin®, a non-addictive analgesic that the company says has shown promising results in clinical trials for the treatment of various types of pain. The company will also showcase its broader peptide therapy pipeline, which includes drug candidates targeting conditions like inflammation, neurological disorders, and metabolic diseases.

  • The LSX Investival conference will take place on March 15-16, 2026 in Miami, Florida.

The players

PVP Labs

A pharmaceutical company focused on developing innovative peptide-based therapies.

Taphalgin®

PVP Labs' non-addictive pain medication that has shown promising results in clinical trials.

LSX Investival

An upcoming industry conference where PVP Labs will present its peptide therapy pipeline and Taphalgin®.

Got photos? Submit your photos here. ›

What’s next

PVP Labs' presentation at LSX Investival will provide a first look at the company's peptide therapy pipeline and its non-addictive pain medication Taphalgin®, which could generate significant interest from investors and industry partners.

The takeaway

PVP Labs' focus on developing innovative peptide-based therapies, including a non-addictive pain medication, highlights the industry's efforts to find alternative treatments that can reduce reliance on opioid painkillers and address unmet medical needs.